Britta Stordal

Summary

Affiliation: Trinity College
Country: Ireland

Publications

  1. pmc Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
    Britta Stordal
    National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
    PLoS ONE 7:e40717. 2012
  2. ncbi request reprint BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
    Britta Stordal
    Department of Histopathology, St James Hospital and Trinity College Dublin, Dublin 8, Ireland
    Mol Oncol 7:567-79. 2013
  3. ncbi request reprint Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells
    Ben Doherty
    Department of Histopathology, Trinity College Dublin, 1 18 Sir Patrick Dun Research Laboratory, Central Pathology Building, St James Hospital, Dublin 8, Ireland
    Anticancer Res 34:503-7. 2014
  4. ncbi request reprint PARP Inhibitors as P-glyoprotein Substrates
    Denise Lawlor
    Department of Histopathology, St James Hospital and Trinity College, Dublin, Dublin 8, Ireland
    J Pharm Sci 103:1913-20. 2014
  5. ncbi request reprint A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1
    Britta Stordal
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Curr Cancer Drug Targets 9:354-65. 2009
  6. doi request reprint Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review
    Mark Murphy
    National Institute for Cellular Biotechnology, Dublin City University, Ireland
    Drug Resist Updat 14:177-90. 2011

Collaborators

Detail Information

Publications7

  1. pmc Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
    Britta Stordal
    National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
    PLoS ONE 7:e40717. 2012
    ..Mechanisms characterised in IGROVCDDP cells may be applicable to relapsed ovarian cancer patients treated with frontline platinum/taxane chemotherapy...
  2. ncbi request reprint BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
    Britta Stordal
    Department of Histopathology, St James Hospital and Trinity College Dublin, Dublin 8, Ireland
    Mol Oncol 7:567-79. 2013
    ..PARP inhibitors may be useful in patients with BRCA1 deleterious mutations or gene methylation...
  3. ncbi request reprint Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells
    Ben Doherty
    Department of Histopathology, Trinity College Dublin, 1 18 Sir Patrick Dun Research Laboratory, Central Pathology Building, St James Hospital, Dublin 8, Ireland
    Anticancer Res 34:503-7. 2014
    ..KB-8-5-11 has become sensitive to non-ABCB1 substrate cisplatin. Understanding the mechanism of collateral sensitivity to cisplatin may lead to biomarker discovery for platinum sensitivity in patients with cancer...
  4. ncbi request reprint PARP Inhibitors as P-glyoprotein Substrates
    Denise Lawlor
    Department of Histopathology, St James Hospital and Trinity College, Dublin, Dublin 8, Ireland
    J Pharm Sci 103:1913-20. 2014
    ..Veliparib and CEP-8983 do not appear to be substrates. Veliparib and CEP-8983 may therefore be more useful in combined chemotherapy regimens with P-gp substrates and may be active in platinum and taxane-resistant ovarian cancer...
  5. ncbi request reprint A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1
    Britta Stordal
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Curr Cancer Drug Targets 9:354-65. 2009
    ..We propose that BRCA1 should be the first of a panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance phenotype...
  6. doi request reprint Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review
    Mark Murphy
    National Institute for Cellular Biotechnology, Dublin City University, Ireland
    Drug Resist Updat 14:177-90. 2011
    ....